These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3481554)

  • 1. Effects of polylactic acid microcapsules containing prostaglandin E2 on the survival rates of grade II coma galactosamine induced fulminant hepatic failure rats.
    Zhou MX; Chang TM
    Biomater Artif Cells Artif Organs; 1987; 15(3):549-58. PubMed ID: 3481554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of prostaglandin E2 on brain edema and liver histopathology in a galactosamine-induced fulminant hepatic failure rat model.
    Dixit V; Chang TM
    Biomater Artif Cells Artif Organs; 1987; 15(3):559-73. PubMed ID: 3481555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control release of prostaglandin E2 from polylactic acid microcapsules, microparticles and modified microparticles.
    Zhou MX; Chang TM
    J Microencapsul; 1988; 5(1):27-36. PubMed ID: 3199299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of prostaglandin E2 on the survival time of fulminant hepatic failure rats.
    Dixit V; Chang TM
    Int J Artif Organs; 1982 Nov; 5(6):388. PubMed ID: 7160937
    [No Abstract]   [Full Text] [Related]  

  • 5. Preliminary report on effects of prostaglandin E2 on brain edema in fulminant hepatic failure rats.
    Dixit V; Chang TM
    Int J Artif Organs; 1985 Jan; 8(1):55-6. PubMed ID: 3855843
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioartificial liver: implanted artificial cells microencapsulated living hepatocytes increases survival of liver failure rats.
    Wong H; Chang TM
    Int J Artif Organs; 1986 Sep; 9(5):335-6. PubMed ID: 3781665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microencapsulation and controlled release of insulin from polylactic acid microcapsules.
    Lin SY; Ho LT; Chiou HL
    Biomater Med Devices Artif Organs; 1985-1986; 13(3-4):187-201. PubMed ID: 3915873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of surface active agents on drug release from polylactic acid-hydrocortisone microcapsules.
    Leelarasamee N; Howard SA; Ma JK
    J Microencapsul; 1988; 5(1):37-46. PubMed ID: 3199300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual evoked potentials in a rabbit model of hepatic encephalopathy. II. Comparison of hyperammonemic encephalopathy, postictal coma, and coma induced by synergistic neurotoxins.
    Pappas SC; Ferenci P; Schafer DF; Jones EA
    Gastroenterology; 1984 Mar; 86(3):546-51. PubMed ID: 6693016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of polylactic acid microcapsules containing ciprofloxacin.
    Yu WP; Wong JP; Chang TM
    J Microencapsul; 1998; 15(4):515-23. PubMed ID: 9651872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain edema and the blood brain barrier in galactosamine-induced fulminant hepatic failure rats. An animal model for evaluation of liver support systems.
    Dixit V; Chang TM
    ASAIO Trans; 1990; 36(1):21-7. PubMed ID: 2306387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microencapsulation using poly(L-lactic acid) IV: Release properties of microcapsules containing phenobarbitone.
    Jalil R; Nixon JR
    J Microencapsul; 1990; 7(1):53-66. PubMed ID: 2308054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hepatic stimulatory factor released from free or microencapsulated hepatocytes on galactosamine induced fulminant hepatic failure animal model.
    Kashani SA; Chang TM
    Biomater Artif Cells Immobilization Biotechnol; 1991; 19(3):565-77. PubMed ID: 1760491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on variation of plasma gamma-aminobutyric acid concentration in rat model of hepatic encephalopathy due to fulminant hepatic failure].
    He X; Luan Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1992 Mar; 23(1):45-8. PubMed ID: 1398623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial liver: the effect of ACAC microencapsulated charcoal hemoperfusion on fulminant hepatic failure.
    Chirito E; Reiter B; Lister C; Chang TM
    Artif Organs; 1977 Aug; 1(1):76-83. PubMed ID: 616275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer.
    Ogawa Y; Yamamoto M; Takada S; Okada H; Shimamoto T
    Chem Pharm Bull (Tokyo); 1988 Apr; 36(4):1502-7. PubMed ID: 3138032
    [No Abstract]   [Full Text] [Related]  

  • 17. Middle molecules in the serum, brain, liver and urine of galactosamine-induced fulminant hepatic failure rats.
    Shu CD; Chang TM
    Int J Artif Organs; 1983 Sep; 6(5):273-7. PubMed ID: 6642726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A method for the preparation of polylactic acid microcapsules of controlled particle size and drug loading.
    Leelarasamee N; Howard SA; Malanga CJ; Ma JK
    J Microencapsul; 1988; 5(2):147-57. PubMed ID: 3199303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties.
    Jalil R; Nixon JR
    J Microencapsul; 1990; 7(3):297-325. PubMed ID: 2200861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microencapsulation using poly(DL-lactic acid). IV: Effect of storage on the microcapsule characteristics.
    Jalil R; Nixon JR
    J Microencapsul; 1990; 7(3):375-83. PubMed ID: 2384839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.